MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: Neuroprotection Trial

Phase 3

Completed

• Conditions: Complications of preterm infant; Neuroprotection; Cerebral Palsy; Child health; Reproductive Health and Childbirth - Antenatal care; Reproductive Health and Childbirth - Complications of newborn; Neurological - Other neurological disorders

• Registration Number: ACTRN12611000491965
• Lead Sponsor: niversity of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-11
• Study Completion: 2020-06-09
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 1679

Inclusion Criteria

Women are eligible for the trial if they are at risk of preterm birth between 30 and 34 weeks’ gestation where birth is planned or definitely expected within 24 hours, have a singleton or twin pregnancy, no contraindications to the use of antenatal magnesium sulphate (myasthenia gravis, respiratory depression, hypotension, absent patellar reflexes or renal failure) and give informed, written consent.

Exclusion Criteria

Women are not eligible if they have a higher-order multiple pregnancy, have already received antenatal magnesium sulphate or if magnesium sulphate therapy is considered essential for the treatment of pre-eclampsia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of death or cerebral palsy defined as stillbirth, death of live born infant before hospital discharge, or death after hospital discharge before 2 years' corrected age; or any cerebral palsy [abnormality of tone with motor dysfunction].[ 2 years' corrected age.]